Resultats de la cerca - Peter Stopfer

  • Mostrar 1 - 15 resultats de 15
Refinar resultats
  1. 1
    Clinical Pharmacokinetics and Pharmacodynamics of Afatinib

    Clinical Pharmacokinetics and Pharmacodynamics of Afatinib per Sven Wind, David Schnell, Thomas Ebner, Matthias Freiwald, Peter Stopfer

    Publicat 2016
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  2. 2
    Phase I Open-Label Study of Continuous Treatment with BIBF 1120, a Triple Angiokinase Inhibitor, and Pemetrexed in Pretreated Non–Small Cell Lung Cancer Patients

    Phase I Open-Label Study of Continuous Treatment with BIBF 1120, a Triple Angiokinase Inhibitor, and Pemetrexed in Pretreated Non–Small Cell Lung Cancer Patients per Peter Ellis, R. Kaiser, Yihua Zhao, Peter Stopfer, Steve Gyorffy, Nasser H. Hanna

    Publicat 2010
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  3. 3
    Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib

    Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib per Sven Wind, Ulrike Schmid, Matthias Freiwald, Kristell Marzin, Ralf Lotz, Thomas Ebner, Peter Stopfer, Claudia Dallinger

    Publicat 2019
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  4. 4
    A Metabolomic Analysis of Sensitivity and Specificity of 23 Previously Proposed Biomarkers for Renal Transporter‐Mediated Drug‐Drug Interactions

    A Metabolomic Analysis of Sensitivity and Specificity of 23 Previously Proposed Biomarkers for Renal Transporter‐Mediated Drug‐Drug Interactions per Arne Gessner, Fabian Müller, Pia Wenisch, Markus R. Heinrich, Jörg König, Peter Stopfer, Martin F. Fromm

    Publicat 2023
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  5. 5
    A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer

    A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung c... per Martin Reck, R. Kaiser, C. Eschbach, Martin Štefanič, James Love, U. Gatzemeier, Peter Stopfer, Joachim von Pawel

    Publicat 2011
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  6. 6
    A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies

    A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies per Andreas du Bois, Jens Huober, Peter Stopfer, J. Pfisterer, Pauline Wimberger, Sibylle Loibl, Volker L. Reichardt, Philipp Harter

    Publicat 2009
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  7. 7
    Evaluation of Solubility-Limited Absorption as a Surrogate to Predicting Positive Food Effect of BCS II/IV Drugs

    Evaluation of Solubility-Limited Absorption as a Surrogate to Predicting Positive Food Effect of BCS II/IV Drugs per Karine Rodríguez-Fernández, José David Gómez‐Mantilla, Suneet Shukla, Peter Stopfer, Peter Sieger, Víctor Mangas-Sanjuán, Sheila Annie Peters

    Publicat 2025
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  8. 8
    A Comprehensive Whole-Body Physiologically Based Pharmacokinetic Drug–Drug–Gene Interaction Model of Metformin and Cimetidine in Healthy Adults and Renally Impaired Individuals

    A Comprehensive Whole-Body Physiologically Based Pharmacokinetic Drug–Drug–Gene Interaction Model of Metformin and Cimetidine in Healthy Adults and Renally Impaired Individuals per Nina Hanke, Denise Türk, Dominik Selzer, Naoki Ishiguro, Thomas Ebner, Sabrina Wiebe, Fabian Müller, Peter Stopfer, Valerie Nock, Thorsten Lehr

    Publicat 2020
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  9. 9
    <scp>N<sup>1</sup></scp>‐Methylnicotinamide as Biomarker for <scp>MATE</scp>‐Mediated Renal Drug–Drug Interactions: Impact of Cimetidine, Rifampin, Verapamil, and Probenecid

    <scp>N<sup>1</sup></scp>‐Methylnicotinamide as Biomarker for <scp>MATE</scp>‐Mediated Renal Drug–Drug Interactions: Impact of Cimetidine, Rifampin, Verapamil, and Probenecid per Fabian Müller, Kathrin Hohl, Sascha Keller, Sven Schmidt‐Gerets, Birgit Deutsch, Annette Schuler‐Metz, Martin F. Fromm, Peter Stopfer, Arne Gessner

    Publicat 2023
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  10. 10
    A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancer

    A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced... per Robert C. Doebele, Paul Conkling, Anne M. Traynor, Gregory A. Otterson, Yanyan Zhao, Sven Wind, Peter Stopfer, R. Kaiser, D. Ross Camidge

    Publicat 2012
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  11. 11
    Pharmacokinetic Evaluation of a Drug Transporter Cocktail Consisting of Digoxin, Furosemide, Metformin, and Rosuvastatin

    Pharmacokinetic Evaluation of a Drug Transporter Cocktail Consisting of Digoxin, Furosemide, Metformin, and Rosuvastatin per Peter Stopfer, Thomas Gießmann, Kathrin Hohl, Añil Sharma, Naoki Ishiguro, ME Taub, Heike Zimdahl‐Gelling, Dietmar Ganßer, Martina Wein, Thomas Ebner, Fabian Müller

    Publicat 2016
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  12. 12
    Optimization of a drug transporter probe cocktail: potential screening tool for transporter‐mediated drug–drug interactions

    Optimization of a drug transporter probe cocktail: potential screening tool for transporter‐mediated drug–drug interactions per Peter Stopfer, Thomas Gießmann, Kathrin Hohl, Sabine Hutzel, Sven Schmidt, Dietmar Ganßer, Naoki Ishiguro, Mitchell E. Taub, Ashish Sharma, Thomas Ebner, Fabian Müller

    Publicat 2018
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  13. 13
    A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours

    A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off sc... per F. Eskens, Constantijne H. Mom, André Planting, Jourik A. Gietema, A. Amelsberg, Holger Huisman, Leni van Doorn, Henry Burger, Peter Stopfer, Jaap Verweij, Elisabeth G.E. de Vries

    Publicat 2007
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  14. 14
    Validation of a Drug Transporter Probe Cocktail Using the Prototypical Inhibitors Rifampin, Probenecid, Verapamil, and Cimetidine

    Validation of a Drug Transporter Probe Cocktail Using the Prototypical Inhibitors Rifampin, Probenecid, Verapamil, and Cimetidine per Sabrina Wiebe, Thomas Gießmann, Kathrin Hohl, Sven Schmidt‐Gerets, Edith Hauel, Alen Jambrecina, Kerstin Bader, Naoki Ishiguro, Mitchell E. Taub, Ashish Sharma, Thomas Ebner, Gerd Mikus, Martin F. Fromm, Fabian Müller, Peter Stopfer

    Publicat 2020
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  15. 15
    Phase I Trial of the Irreversible EGFR and HER2 Kinase Inhibitor BIBW 2992 in Patients With Advanced Solid Tumors

    Phase I Trial of the Irreversible EGFR and HER2 Kinase Inhibitor BIBW 2992 in Patients With Advanced Solid Tumors per Timothy A. Yap, Laura Vidal, Jan Adam, Peter Stephens, James Spicer, Heather Shaw, J.E. Ang, Graham Temple, Susan Bell, Mehdi Shahidi, Martina Uttenreuther‐Fischer, Peter Stopfer, P. Andrew Futreal, Hilary Calvert, Johann S. de Bono, Ruth Plummer

    Publicat 2010
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:

Eines de cerca: